Parameter
| Biomarker | FGFR | Full name | Fibroblast growth factor receptor | Molecular Type | Protein / Nucleic acid |
|---|---|---|---|---|---|
| Molecular Formula | / | Molecular Weight | / | Core Functional Dimensions | Prognosis |
| Disease | Breast Cancer | Disease Subtypes | / | ||
| Organ | Breast | Test Sample / Technology Platform | Tumor tissue / ctDNA (NGS, FISH) | ||
| Pathobiological Mechanisms | FGFR gene amplification or mutation activates downstream signaling pathways, which can lead to HER2 treatment resistance, promote tumor angiogenesis and metastasis. | ||||
| Clinical Availability Status | Research validation / clinical trial: FGFR inhibitors (such as erdafitinib) are in Phase II/III clinical trials for advanced breast cancer with FGFR amplification / mutation. | ||||
| Notes and Dynamics | The combined inhibition of FGFR and HER2 can overcome some HER2 resistance. Relevant combined drug trial is currently underway. | ||||